PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for Samuel Garcia�
3.52
+0.01 (0.28%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.48 - 3.57
52 week 2.58 - 6.20
Open 3.49
Vol / Avg. 0.00/1.21M
Mkt cap 582.86M
P/E 1.90
Div/yield 0.05/5.68
EPS 1.85
Shares 165.11M
Beta 0.65
Inst. own 79%
Aug 4, 2016
Q2 2016 PDL BioPharma Inc Earnings Release - Tentative - 4:00PM EDT - Add to calendar
Jul 6, 2016
PDL BioPharma Inc Closes Equity Investment Transaction in Noden Pharma for the Acquisition of Tekturna and Tekturna HCT - Conference Call
Jun 7, 2016
PDL BioPharma Inc at Jefferies Healthcare Conference - Webcast
Jun 2, 2016
PDL BioPharma Inc Annual Shareholders Meeting
May 27, 2016
PDL BioPharma Inc Annual Shareholders Meeting (Estimated)
May 4, 2016
Q1 2016 PDL BioPharma Inc Earnings Call
May 4, 2016
Q1 2016 PDL BioPharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 54.19% 56.36%
Operating margin 90.45% 94.31%
EBITD margin - 93.89%
Return on average assets 21.68% 33.71%
Return on average equity 31.17% 57.56%
Employees 10 -
CDP Score - -

Address

932 Southwood Blvd
INCLINE VILLAGE, NV 89451
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.

Officers and directors

John Peter McLaughlin President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 53
Bio & Compensation  - Reuters
Steffen Pietzke CPA Chief Accounting Officer, Controller
Age: 43
Bio & Compensation  - Reuters
Christopher Lewis Stone Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Danny Hart Vice President - Business Development
Age: 39
Bio & Compensation  - Reuters
Paul R. Edick Director
Age: 60
Bio & Compensation  - Reuters
Samuel R. Saks M.D. Director
Age: 60
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 60
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 63
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 67
Bio & Compensation  - Reuters